Trials Sponsors Conditions Drugs Pricing

Conditions

Lung Diseases Lung Diseases, Interstitial Pulmonary Fibrosis Respiratory Tract Diseases

Keywords

Idiopathic Pulmonary FibrosisInterferon alpha

Outcome Measures

Primary Outcomes (2)

Minimal/no Progression (1 yr) by High Resolution Computed Tomography (HRCT) & Pulmonary Function
Disease progression was determined by comparing results of the High Resolution Computed Tomography(HRCT) and pulmonary function at one year to the baseline HRCT \& pulmonary function. The same radiologist did the comparsion for all subjects.
1 yr
Minimal/no Change in Quality of Life
12 months

Secondary Outcomes (1)

Participants With Change in Cough
1 month

Interventions

Interferon alpha oral lozengeDrug

dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age50 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

The only subjects to be included in this study are those diagnosed with Idiopathic Pulmonary Fibrosis with diagnosis based on the criteria published by the American Thoracic Society in the International Consensus Statement.
Abnormal pulmonary function studies.

Sponsors & Collaborators

Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industrycollaborator
Texas Tech University Health Sciences Center
Otherlead

Study Sites (1)

Texas Tech University Health Sciences Center

Lubbock, Texas, 79430, United States

MeSH Terms

Conditions

Respiratory Tract DiseasesLung DiseasesLung Diseases, InterstitialPulmonary FibrosisIdiopathic Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

FibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title: Lorenz Lutherer, MD, PhD
Organization: Texas Tech University Health Sciences Center

Study Officials

Cynthia Jumper, MD
Texas Tech University Health Sciences Center
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: Yes
Restrictive Agreement: No

Enrollment

18 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 23, 2009

First Posted

September 29, 2011

Study Start

September 2000

Date type not reported

This date has not been verified as actual or estimated.

Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations